Trials / Recruiting
RecruitingNCT06356519
Real-world Effectiveness and Safety Study of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer
Effectiveness and Safety of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer: A Multi-center Real-world Retrospective Study
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 150 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this trial is to explore the real-world effectiveness and poteintial predictors of Sacituzumab Govitecan in Chinese metastatic breast cancer patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sacituzumab Govitecan | Sacituzumab Govitecan,10 mg/kg ivgtt d1, d8, q3w |
Timeline
- Start date
- 2024-03-01
- Primary completion
- 2025-03-01
- Completion
- 2025-04-01
- First posted
- 2024-04-10
- Last updated
- 2024-04-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06356519. Inclusion in this directory is not an endorsement.